LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center in San Antonio, Texas, from December 7-10, 2021. Abstracts are available to the public online on the SABCS website at www.sabcs.org.
|
Oral Presentation:
|
|
|
|
|
|
|
|
Abstract:
|
|
GS4-10
|
|
Title:
|
|
Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
|
|
Presenter:
|
|
Komal Jhaveri, MD, FACP
|
|
Session:
|
|
Friday, Dec. 10, 11:00-11:15 a.m. CT
|
|
|
|
|
|
Poster Presentations:
|
|
|
|
|
|
|
|
Abstract:
|
|
P2-10-08
|
|
Title:
|
|
Assessment of risk factors for HER2+ breast cancer recurrence: A literature review
|
|
Presenter:
|
|
Joyce O'Shaughnessy, M.D.
|
|
Session:
|
|
PosterSession 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
|
|
|
|
|
|
Abstract:
|
|
P2-11-02
|
|
Title:
|
|
Subsequent breast cancer among women with HER2+ disease in a large integrated healthcare system
|
|
Presenter:
|
|
Reina Haque, PhD, MPH
|
|
Session:
|
|
PosterSession 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
|
|
|
|
|
|
Abstract:
|
|
P2-11-19
|
|
Title:
|
|
Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC)
|
|
Presenter:
|
|
David Leroy Veenstra, PharmD, PhD
|
|
Session:
|
|
PosterSession 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
|
|
|
|
|
|
Abstract:
|
|
P2-13-05
|
|
Title:
|
|
Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)
|
|
Presenter:
|
|
Nancy U. Lin, MD
|
|
Session:
|
|
PosterSession 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
|
|
|
|
|
|
Abstract:
|
|
P2-13-21
|
|
Title:
|
|
Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
|
|
Presenter:
|
|
Frankie Ann Homes, MD, FACP
|
|
Session:
|
|
PosterSession 2, Wednesday, Dec. 8, 5:00-6:30 p.m. CT
|
|
|
|
|
|
Abstract:
|
|
P3-12-20
|
|
Title:
|
|
Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer
|
|
Presenter:
|
|
Joyce O'Shaughnessy, M.D.
|
|
Session:
|
|
PosterSession 3, Thursday, Dec. 9, 7:00-8:30 a.m. CT
|
|
|
|
|
|
Abstract:
|
|
P3-16-01
|
|
Title:
|
|
Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
|
|
Presenter:
|
|
David Leroy Veenstra, PharmD, PhD
|
|
Session:
|
|
PosterSession 3, Thursday, Dec. 9, 7:00-8:30 a.m. CT
|
|
|
|
|
|
Abstract:
|
|
P5-18-02
|
|
Title:
|
|
Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer
|
|
Presenter:
|
|
Arlene Chan, MBBS, FRACP, MMED
|
|
Session:
|
|
PosterSession 5, Friday, Dec. 10, 7:00-8:30 a.m. CT
|
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Source: Puma Biotechnology, Inc.